Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score.

Radin M, Cecchi I, Schreiber K, Rubini E, Roccatello D, Cuadrado MJ, Sciascia S.

Semin Arthritis Rheum. 2020 Jan 28. pii: S0049-0172(20)30007-X. doi: 10.1016/j.semarthrit.2020.01.007. [Epub ahead of print]

PMID:
32089355
2.

The Impact of Age and Sex on Mouse Models of Melioidosis.

Klimko CP, Treviño SR, Moreau AM, Cuadrado MJA, Meyer JR, Fetterer DP, Welkos SL, Worsham PL, Kreiselmeier N, Soffler C, Cote CK.

Pathogens. 2020 Feb 11;9(2). pii: E113. doi: 10.3390/pathogens9020113.

3.

Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review.

Gilcrease GW, Padovan D, Heffler E, Peano C, Massaglia S, Roccatello D, Radin M, Cuadrado MJ, Sciascia S.

Eur J Rheumatol. 2020 Jan 1;7(1):31-34. doi: 10.5152/eurjrheum.2019.19141. Print 2020 Jan. Review.

4.

Prevalence of Antiphospholipid Antibodies Negativisation in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Multicentre Study.

Radin M, Schreiber K, Sciascia S, Roccatello D, Cecchi I, Aguirre Zamorano MÁ, Cuadrado MJ.

Thromb Haemost. 2019 Dec;119(12):1920-1926. doi: 10.1055/s-0039-1696687. Epub 2019 Oct 6.

PMID:
31587246
5.

Immunoglobulin abnormalities are frequent in patients with lupus nephritis.

Cuadrado MJ, Calatayud I, Urquizu-Padilla M, Wijetilleka S, Kiani-Alikhan S, Karim MY.

BMC Rheumatol. 2019 Aug 21;3:30. doi: 10.1186/s41927-019-0079-2. eCollection 2019.

6.

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM.

Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.

PMID:
31092409
7.

Pregnancy outcomes in mixed connective tissue disease: a multicentre study.

Radin M, Schreiber K, Cuadrado MJ, Cecchi I, Andreoli L, Franceschini F, Caleiro T, Andrade D, Gibbone E, Khamashta M, Buyon J, Izmirly P, Aguirre MA, Benedetto C, Roccatello D, Marozio L, Sciascia S.

Rheumatology (Oxford). 2019 Nov 1;58(11):2000-2008. doi: 10.1093/rheumatology/kez141.

PMID:
31079145
8.

Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study.

Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D.

Ann Rheum Dis. 2019 Jul;78(7):1004-1006. doi: 10.1136/annrheumdis-2018-214559. Epub 2018 Dec 14. No abstract available.

9.

Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?

Enriquez Merayo E, Sciascia S, Roccatello D, Cuadrado MJ.

Expert Rev Clin Immunol. 2018 Nov;14(11):877-879. doi: 10.1080/1744666X.2018.1527219. Epub 2018 Oct 17. No abstract available.

PMID:
30328733
10.

Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome.

Pérez-Sánchez C, Arias-de la Rosa I, Aguirre MÁ, Luque-Tévar M, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, Ábalos-Aguilera MC, Collantes-Estévez E, Segui P, Velasco F, Herranz MT, Lozano-Herrero J, Hernandez-Vidal MJ, Martínez C, González-Conejero R, Radin M, Sciascia S, Cecchi I, Cuadrado MJ, López-Pedrera C.

Haematologica. 2018 May;103(5):908-918. doi: 10.3324/haematol.2017.184416. Epub 2018 Mar 15.

11.

Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.

Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado MJ, Latino JO, Udry S, Reshetnyak T, Costedoat-Chalumeau N, Morel N, Marozio L, Tincani A, Andreoli L, Haladyj E, Meroni PL, Gerosa M, Alijotas-Reig J, Tenti S, Mayer-Pickel K, Simchen MJ, Bertero MT, De Carolis S, Ramoni V, Mekinian A, Grandone E, Maina A, Serrano F, Pengo V, Khamashta MA.

Thromb Haemost. 2018 Apr;118(4):639-646. doi: 10.1055/s-0038-1632388. Epub 2018 Feb 28.

12.

Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.

Ouvry G, Atrux-Tallau N, Bihl F, Bondu A, Bouix-Peter C, Carlavan I, Christin O, Cuadrado MJ, Defoin-Platel C, Deret S, Duvert D, Feret C, Forissier M, Fournier JF, Froude D, Hacini-Rachinel F, Harris CS, Hervouet C, Huguet H, Lafitte G, Luzy AP, Musicki B, Orfila D, Ozello B, Pascau C, Pascau J, Parnet V, Peluchon G, Pierre R, Piwnica D, Raffin C, Rossio P, Spiesse D, Taquet N, Thoreau E, Vatinel R, Vial E, Hennequin LF.

ChemMedChem. 2018 Feb 20;13(4):321-337. doi: 10.1002/cmdc.201700758. Epub 2018 Feb 6.

PMID:
29327456
13.

The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study.

Radin M, Schreiber K, Cecchi I, Roccatello D, Cuadrado MJ, Sciascia S.

Eur J Neurol. 2018 Feb;25(2):320-325. doi: 10.1111/ene.13499. Epub 2017 Dec 2.

14.

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Sciascia S, Coloma-Bazán E, Radin M, Bertolaccini ML, López-Pedrera C, Espinosa G, Meroni PL, Cervera R, Cuadrado MJ.

Autoimmun Rev. 2017 Nov;16(11):1109-1114. doi: 10.1016/j.autrev.2017.09.004. Epub 2017 Sep 9. Review.

15.

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, Gonzalez E, Knight JS, Uthman I, Willis R, Zhang Z, Wahl D, Zuily S, Tektonidou MG; APS ACTION.

Lupus. 2018 Mar;27(3):399-406. doi: 10.1177/0961203317724219. Epub 2017 Aug 1.

PMID:
28764618
16.

Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.

Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, Ábalos-Aguilera MC, Jiménez-Gómez Y, Arias-de la Rosa I, Rodriguez-Ariza A, Fernández-Del Río L, González-Reyes JA, Segui P, Collantes-Estévez E, Barbarroja N, Velasco F, Sciascia S, Cecchi I, Cuadrado MJ, Villalba JM, López-Pedrera C.

Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932. doi: 10.1161/ATVBAHA.117.309225. Epub 2017 Jul 6.

PMID:
28684614
17.

The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction.

Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, Bazzan M, Cuadrado MJ, Sciascia S.

Int J Cardiol. 2017 Aug 1;240:72-77. doi: 10.1016/j.ijcard.2017.02.155. Epub 2017 Mar 24.

18.

Rate of Adverse Effects of Medium- to High-Dose Glucocorticoid Therapy in Systemic Lupus Erythematosus: A Systematic Review of Randomized Control Trials.

Sciascia S, Mompean E, Radin M, Roccatello D, Cuadrado MJ.

Clin Drug Investig. 2017 Jun;37(6):519-524. doi: 10.1007/s40261-017-0518-z. Review.

19.

Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban.

Crowley MP, Cuadrado MJ, Hunt BJ.

Thromb Res. 2017 May;153:37-39. doi: 10.1016/j.thromres.2017.03.006. Epub 2017 Mar 8. No abstract available.

PMID:
28319823
20.

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Sciascia S, Radin M, Yazdany J, Levy RA, Roccatello D, Dall'Era M, Cuadrado MJ.

Autoimmun Rev. 2017 Mar;16(3):287-293. doi: 10.1016/j.autrev.2017.01.010. Epub 2017 Jan 29. Review.

21.

Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.

Radin M, Sciascia S, Roccatello D, Cuadrado MJ.

BioDrugs. 2017 Feb;31(1):37-49. doi: 10.1007/s40259-016-0206-1. Review.

22.

'Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patients'.

Pérez-Sánchez C, Aguirre MA, Ruiz-Limón P, Barbarroja N, Jiménez-Gómez Y, de la Rosa IA, Rodriguez-Ariza A, Collantes-Estévez E, Segui P, Velasco F, Cuadrado MJ, Teruel R, González-Conejero R, Martínez C, López-Pedrera Ch.

Sci Rep. 2016 Aug 9;6:31375. doi: 10.1038/srep31375.

23.

Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay.

Sciascia S, Baldovino S, Schreiber K, Solfietti L, Radin M, Cuadrado MJ, Menegatti E, Erkan D, Roccatello D.

Clin Mol Allergy. 2016 Jul 15;14:6. doi: 10.1186/s12948-016-0043-2. eCollection 2016. Review.

24.

Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches.

López-Pedrera C, Barbarroja N, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ.

Rheumatology (Oxford). 2016 Dec;55(12):2096-2108. Epub 2016 Mar 27. Review.

PMID:
27018059
25.

Emerging therapies in systemic lupus erythematous: from clinical trial to the real life.

Zhang H, Chambers W, Sciascia S, Cuadrado MJ.

Expert Rev Clin Pharmacol. 2016;9(5):681-94. doi: 10.1586/17512433.2016.1155446. Epub 2016 Mar 10. Review.

26.

Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.

Sciascia S, Lopez-Pedrera C, Cecchi I, Pecoraro C, Roccatello D, Cuadrado MJ.

Rheumatology (Oxford). 2016 Oct;55(10):1726-35. doi: 10.1093/rheumatology/kev445. Epub 2016 Feb 3. Review.

27.

The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.

Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ.

Am J Obstet Gynecol. 2016 Feb;214(2):273.e1-273.e8. doi: 10.1016/j.ajog.2015.09.078. Epub 2015 Sep 30.

28.

Immunotherapy in antiphospholipid syndrome.

Lopez-Pedrera Ch, Aguirre MA, Ruiz-Limon P, Pérez-Sánchez C, Jimenez-Gomez Y, Barbarroja N, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):200-8. doi: 10.1016/j.intimp.2015.06.006. Epub 2015 Jun 15. Review.

PMID:
26086363
29.

Upcoming biological therapies in systemic lupus erythematosus.

Sciascia S, Talavera-Garcia E, Roccatello D, Baldovino S, Mengatti E, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):189-93. doi: 10.1016/j.intimp.2015.04.049. Epub 2015 May 28. Review.

30.

Thematic issue: Biologics in autoimmune diseases.

Sciascia S, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):179. doi: 10.1016/j.intimp.2015.05.006. Epub 2015 May 8. No abstract available.

31.

Biosimilar vs biological agents in rheumatology: When are biosimilar agents similar enough?

Lie G, Sciascia S, Cuadrado MJ.

Int Immunopharmacol. 2015 Aug;27(2):220-3. doi: 10.1016/j.intimp.2015.04.022. Epub 2015 Apr 20. Review.

32.

Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection.

Simoes J, Sciascia S, Camara I, Baldovino S, Karim Y, Roccatello D, Cuadrado MJ.

J Clin Rheumatol. 2015 Jan;21(1):35-7. doi: 10.1097/RHU.0000000000000201. No abstract available.

33.

Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort.

Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1915-20. doi: 10.1002/acr.22388.

34.

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review.

Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, Bertolaccini ML; APS Action.

Ann Rheum Dis. 2015 Nov;74(11):2028-33. doi: 10.1136/annrheumdis-2014-205663. Epub 2014 Jun 18. Review.

35.

Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.

Ruiz-Limon P, Barbarroja N, Perez-Sanchez C, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Almadén Y, Segui P, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Collantes-Estevez E, Cuadrado MJ, Lopez-Pedrera C.

Ann Rheum Dis. 2015 Jul;74(7):1450-8. doi: 10.1136/annrheumdis-2013-204351. Epub 2014 Mar 21.

PMID:
24658835
36.

Renal involvement in antiphospholipid syndrome.

Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D.

Nat Rev Nephrol. 2014 May;10(5):279-89. doi: 10.1038/nrneph.2014.38. Epub 2014 Mar 18. Review.

37.

Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.

Perez-Sanchez C, Barbarroja N, Messineo S, Ruiz-Limon P, Rodriguez-Ariza A, Jimenez-Gomez Y, Khamashta MA, Collantes-Estevez E, Cuadrado MJ, Aguirre MA, Lopez-Pedrera C.

Ann Rheum Dis. 2015 Jul;74(7):1441-9. doi: 10.1136/annrheumdis-2013-204600. Epub 2014 Mar 11.

PMID:
24618261
38.

14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.

Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, Levy RA, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Willis R, Lockshin MD.

Autoimmun Rev. 2014 Jun;13(6):685-96. doi: 10.1016/j.autrev.2014.01.053. Epub 2014 Jan 24. Review.

PMID:
24468415
39.

Management of infection in systemic lupus erythematosus.

Sciascia S, Cuadrado MJ, Karim MY.

Best Pract Res Clin Rheumatol. 2013 Jun;27(3):377-89. doi: 10.1016/j.berh.2013.07.002. Review.

40.

Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS).

Cuadrado MJ, Bertolaccini ML, Seed PT, Tektonidou MG, Aguirre A, Mico L, Gordon C, Ruiz-Irastorza G, Egurbide MV, Gil A, Espinosa G, Houssiau F, Rahman A, Martin H, McHugh N, Galindo M, Akil M, Amigo MC, Murru V, Khamashta MA.

Rheumatology (Oxford). 2014 Feb;53(2):275-84. doi: 10.1093/rheumatology/ket313. Epub 2013 Oct 4.

PMID:
24097288
41.

Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.

Camara I, Sciascia S, Simoes J, Pazzola G, Salas V, Karim Y, Roccatello D, Cuadrado MJ.

Clin Exp Rheumatol. 2014 Jan-Feb;32(1):41-7. Epub 2013 Sep 12.

PMID:
24029366
42.

SER consensus statement on the use of biologic therapy for systemic lupus erythematosus.

Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, Pego-Reigosa JM, Olivé A, Martínez-Fernández C, Martínez-Taboada V, Luis Marenco J, Loza E, López-Longo J, Gómez-Reino JJ, Galindo-Izquierdo M, Fernández-Nebro A, Cuadrado MJ, Aguirre-Zamorano MÁ, Zea-Mendoza A, Rúa-Figueroa I; Sociedad Española de Reumatología.

Reumatol Clin. 2013 Sep-Oct;9(5):281-96. doi: 10.1016/j.reuma.2013.04.001. Epub 2013 Jul 17. English, Spanish.

43.

Is it time for biosimilars in autoimmune diseases?

Cuadrado MJ, Sciascia S, Bosch X, Khamashta MA, Ramos-Casals M.

Autoimmun Rev. 2013 Aug;12(10):954-7. doi: 10.1016/j.autrev.2013.02.005. Epub 2013 Mar 28. Review.

44.

Catastrophic antiphospholipid syndrome (CAPS).

Sciascia S, Lopez-Pedrera C, Roccatello D, Cuadrado MJ.

Best Pract Res Clin Rheumatol. 2012 Aug;26(4):535-41. doi: 10.1016/j.berh.2012.07.005. Review.

45.

Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment.

Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C.

Blood. 2012 Jun 14;119(24):5859-70. doi: 10.1182/blood-2011-12-400986. Epub 2012 Apr 23.

PMID:
22529290
46.

Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.

Sciascia S, Ceberio L, Garcia-Fernandez C, Roccatello D, Karim Y, Cuadrado MJ.

Autoimmun Rev. 2012 Dec;12(2):157-63. doi: 10.1016/j.autrev.2012.03.009. Epub 2012 Apr 1. Review.

47.

Potential use of statins in the treatment of antiphospholipid syndrome.

Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Rodriguez-Ariza A, Cuadrado MJ.

Curr Rheumatol Rep. 2012 Feb;14(1):87-94. doi: 10.1007/s11926-011-0222-6. Review.

PMID:
22105548
48.

Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS').

Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA.

Ann Rheum Dis. 2012 Feb;71(2):242-4. doi: 10.1136/annrheumdis-2011-200614. Epub 2011 Sep 27.

PMID:
21953349
49.

Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions.

López-Pedrera C, Pérez-Sánchez C, Ramos-Casals M, Santos-Gonzalez M, Rodriguez-Ariza A, Cuadrado MJ.

Clin Dev Immunol. 2012;2012:974648. doi: 10.1155/2012/974648. Epub 2011 Sep 14. Review.

50.

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies.

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M.

Lupus. 2011 Feb;20(2):206-18. doi: 10.1177/0961203310395803.

PMID:
21303837

Supplemental Content

Loading ...
Support Center